Researchers studied 263 postmenopausal women with a specific type of advanced breast cancer. These patients received a first-line treatment consisting of two medications: ribociclib and letrozole. The study tracked the progression of the disease over a period of about 23 months.
The study looked at circulating tumor DNA, which are fragments of genetic material found in the blood. The results showed that certain patterns in these markers were linked to better outcomes. Specifically, patients who did not have detectable mutations at the start or those whose mutations cleared quickly during early treatment showed a lower risk of their cancer progressing.
While these findings suggest that tracking DNA markers could be a helpful way to predict how well a patient responds to therapy, more research is needed. The study notes that these markers are currently considered promising but require further validation before they can be used routinely in clinical practice.
Common questions
What did the study find about treatment for advanced breast cancer?
The study followed 263 postmenopausal women with HR+ and HER2- advanced breast cancer. Patients received ribociclib and letrozole as a first-line treatment. The median progression-free survival was found to be 23.4 months.
How do DNA markers help in this type of treatment?
The study looked at ctDNA, which are genetic fragments in the blood. Patients with no detectable mutations at the start or those who cleared mutations early in treatment showed a lower risk of progression. These findings suggest these markers could be useful for predicting how well a patient responds to therapy.
Is this new method ready to use in clinics?
The study describes these DNA markers as promising prognostic and predictive biomarkers. However, the researchers stated that further studies are needed to fully validate their clinical use before they can be used routinely to guide treatment decisions.
